Correlation between KRAS mutations and clinicopathological features in colorectal carcinomas. A multivariate analysis

Natalia Rodon1, Ruth Roman1, Montse Verdu1,3 ,Miquel Calvo4, Beatriz Garcia-Pelaez1, Marta Gonzalez1, Carme Pubill3 and Xavier Puig1,2,3.

1BIOPAT. Biopatologia Molecular SL, Grup Assistència. 2Hospital de Barcelona-SCIAS, Grup Assistencia. 3Histopat Laboratoris. 4Departament d’Estadística, Facultat de Biologia. UB. Barcelona.

KRAS oncogenic mutations, present in approximately 30-50% of colorectal carcinomas (CRC), result in a lack of response to EGFR inhibitors. The aim of this study was to confirm with a multivariate analysis the correlations observed in our initial univariate approach between KRAS mutational status and […]

2010-05-23T17:23:06+00:00

Molecular characterization of micropapillary variant of colorectal carcinoma. Review of sixty cases

M Verdu1,3, R Roman1, M Calvo4, N Rodon1, B Garcia1, M Gonzalez1 and X Puig1,2,3.

1BIOPAT.Biopatologia Molecular, SL, Grup Assistència, Barcelona, Spain; 2Hospital de Barcelona, SCIAS, Grup Assistència, Barcelona, Spain; 3Histopat Laboratoris, Barcelona, Spain and 4Statistics Department, Universitat Barcelona, Barcelona, Spain.

Background: Micropapillary carcinoma (MC) is accepted as an aggressive variant of colorectal adenocarcinoma, described for the first time in the breast and later in other organs. At present, there are a limited number of colorectal MC series reported, not enough to define […]

2010-03-23T17:21:45+00:00

KRAS mutations correlates with P53 status in colorectal carcinomas

Natalia Rodón1, Ruth Román1, Montse Verdú1,3, Miquel Calvo4, Beatriz García-Peláez1, Marta González1, Carme Pubill3 y Xavier Puig1,2,3.

1BIOPAT. Biopatologia Molecular, SL, Grup Assistència; 2Hospital de Barcelona-SCIAS, Grup Assistència; 3Histopat Laboratoris; 4Departament d’Estadística, Universitat de Barcelona. Barcelona

Background:

KRAS mutations, present in approximately 30-50% of colorectal carcinomas (CRC) has been recently associated with lack of response to anti-EGFR therapy, poor prognosis and high mitotic activity. Nevertheless, its relation to other histopathological and molecular parameters has not been well established.

Our first approach was to determine […]

2009-09-23T17:20:26+00:00

Fórmula de predicción de inestabilidad de microsatélites en el cáncer colorectal en base a parámetros morfológicos. Estudio multicéntrico prospectivo de validación y optimización del modelo

R Román1, M Verdú1,3, A Vidal3,5, M Calvo4, X Sanjuan5, M Jimeno6, A Salas7, J Autonell8, I Trias9, M González1, B García1, N Rodón1 y X Puig1,2,3.

1BIOPAT. Biopatologia Molecular, SL, Grup Assistència; 2Hospital de Barcelona-SCIAS, Grup Assistència; 3Histopat Laboratoris; 4Departament d’Estadística, Universitat de Barcelona; 5Hospital Universitari de Bellvitge; 6Hospital del Mar; 7Hospital Mútua de Terrassa; 8Hospital General de Vic; 9Hospital Plató, Barcelona.

Introducción: La inestabilidad de microsatélites (MSI-H) identifica un grupo de carcinomas colorectales de mejor pronóstico y con riesgo […]

2009-05-23T17:19:19+00:00

Multicentric validation of a model based on phenotypic features to predict microsatellite instability in colorectal adenocarcinoma

R ROMAN1, M VERDU1,3, A VIDAL3,5, M CALVO4, X SANJUAN5, M JIMENO6, A SALAS7, J AUTONELL8, I TRIAS9, N RODON1, M GONZALEZ1, B GARCIA1 and X PUIG1,2,3.

1BIOPAT.Biopatologia Molecular, Barcelona, Spain; 2Hospital de Barcelona, Barcelona, Spain; 3Histopat Laboratoris, Barcelona, Spain; 4Statistics Department, Universitat de Barcelona, Barcelona, Spain; 5Hospital Universitari de Bellvitge, Barcelona, Spain; 6Hospital del Mar, Barcelona, Spain; 7Hospital Mútua de Terrassa, Terrasa, Spain; 8Hospital General de Vic, Vic, Spain and 9Hospital Plató, Barcelona, Spain.

Background: High microsatellite instability (MSI-H) allows the […]

2009-03-23T17:17:26+00:00